Investigator Christopher Jones, MD

Dr. Christopher Jones is a board-certified radiation oncologist who specializes in the use of ionizing radiation to treat cancer, focusing on tumors of the head and neck, prostate, and brain. He investigates optimal use of radiation therapy (radiotherapy) techniques including intensity modulated radiation therapy (IMRT), high-dose brachytherapy, and image-guided radiation therapy. Dr. Jones is a Principal Investigator for Radiation Therapy Oncology Group (RTOG) National Cancer Institute-sponsored oncology group clinical trials. He has authored numerous publications and abstracts on radiotherapy and imaging techniques to assess cancer progression, predict tumor recurrence after surgery and radiotherapy, and visualize response to treatment. Dr. Jones lectures nationally and internationally on the role of radiation therapy in the management of head and neck cancers.

Sutter Health Research Enterprise
2800 L Street, #10
Sacramento, CA, 95816
(916) 454-6600
simr@sutterhealth.org

Primary Research Interests

Related Clinical Trials

Adjuvant (ECOG-ACRIN EA3191)

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra

Investigator: Christopher Jones MD

Status: Active, Recruiting

Adjuvant (NRG BN003)

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Investigator: Christopher Jones MD

Status: Active, Recruiting

Adjuvant (RTOG 3506 STEEL)

A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide)

Investigators: Christopher Jones MD, Sivakumar Reddy M.D., Seth A Rosenthal Radiation Oncologist, David S Yee M.D., MPH

Status: Active, Recruiting

Adjuvant NRG HN001

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Investigator: Christopher Jones MD

Status: Active, Recruiting

First Line or Neoadjuvant (NRG-HN005)

De-intensified Radiation Therapy With Cisplatin or Nivolumab in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Investigator: Christopher Jones MD

Status: Active, Recruiting

Locally Advanced (NRG BN010)

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Investigator: Christopher Jones MD

Status: Active, Recruiting

Locally Advanced (NRG GU005)

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Investigator: Christopher Jones MD

Status: Active, Recruiting

Locally Advanced (NRG HN004) Temporarily on Hold

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Investigator: Christopher Jones MD

Status: Active, Not Recruiting

Locally Advanced (NRG HN009)

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Investigator: Christopher Jones MD

Status: Active, Recruiting

Locally Advanced (RTOG 1216)

Randomized Phase II/III Trial of Adjuvant Radiation Therapy (RT) with Cisplatin, Docetaxel Cetuximab, or Cisplatin Atezolizumab in Pathologic High Risk Squamous

Investigator: Christopher Jones MD

Status: Active, Recruiting